July 27, 2023 08:55 AM EDT
People
R&D

Mer­sana halves work­force in light of ovar­i­an can­cer tri­al flop, spelling end to its lead ADC

Kyle LaHucik

Senior Reporter

Mer­sana Ther­a­peu­tics will lay off about half its work­force and repri­or­i­tize af­ter a Phase III tri­al fail­ure in plat­inum-re­sis­tant ovar­i­an can­cer, send­ing shares $MRSN tank­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times